Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.

Zanger, P; Kötter, I; Kremsner, PG; Gabrysch, S; (2012) Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clinical microbiology and infection, 18 (7). pp. 670-6. ISSN 1198-743X DOI: https://doi.org/10.1111/j.1469-0691.2011.03674.x

Full text not available from this repository. (Request a copy)


: Leishmaniasis is endemic in Europe and the prevalence of latent infection in the Mediterranean region is high. Reports describing opportunistic leishmaniasis in European patients treated with tumor necrosis factor (TNF) alpha antagonist drugs are rapidly accumulating. For other granulomatous infections, risk of opportunistic disease varies by mode of TNF-alpha antagonism. This study explores whether this may also be the case for leishmaniasis. We ascertained the relative frequency of exposure to different TNF antagonist drugs among published cases of opportunistic leishmaniasis in Europe and compared this with the prescription of these drugs in Europe. We found that risk of opportunistic leishmaniasis is higher in patients receiving anti-TNF monoclonal antibodies (infliximab or adalimumab) compared with patients treated with the TNF-receptor construct etanercept. Clinicians may want to consider these observations, which suggest that etanercept should be favoured over anti-TNF monoclonal antibodies in individuals living in or visiting areas endemic for leishmaniasis until evidence from prospective research is available. A European adverse event reporting system is required to identify rare opportunistic infections associated with immunosuppressive and immunomodulatory biotherapies.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Leishmaniasis Group
Centre for Maternal, Reproductive and Child Health (MARCH)
PubMed ID: 21985586
Web of Science ID: 305285200023
URI: http://researchonline.lshtm.ac.uk/id/eprint/588990


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item